BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14586743)

  • 1. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial.
    Kanno Y; Witt M; Okada H; Nemoto H; Sugahara S; Nakamoto H; Suzuki H
    Clin Exp Nephrol; 2003 Mar; 7(1):48-51. PubMed ID: 14586743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
    Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
    Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria.
    Uzu T; Harada T; Ko M; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Sep; 7(3):210-4. PubMed ID: 14586717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of steroid therapy in IgA nephropathy].
    Ohashi T; Shimokawahara H; Fukumoto M; Azuma K; Uchida Y; Tokuda Y; Ito H; Yasumoto Y; Yamashita W; Harada R
    Fukuoka Igaku Zasshi; 1992 May; 83(5):209-15. PubMed ID: 1612550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW; Fluck RJ; Lambie SH
    Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
    Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
    Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C; Del Vecchio L; Locatelli F
    G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
    Manno C; Gesualdo L; D'Altri C; Rossini M; Grandaliano G; Schena FP
    J Nephrol; 2001; 14(4):248-52. PubMed ID: 11506246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.
    Lai KN; Lai FM; Ho CP; Chan KW
    Clin Nephrol; 1986 Oct; 26(4):174-80. PubMed ID: 3536231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy in children and adolescents with IgA nephropathy.
    Murakami K; Yoshioka K; Akano N; Takemura T; Okada M; Aya N; Hino S; Miyazato H; Yagi K; Maki S
    Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
    Walker RG; Yu SH; Owen JE; Kincaid-Smith P
    Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of poor outcomes in steroid therapy for immunoglobulin A nephropathy.
    Shimizu A; Takei T; Uchida K; Tsuchiya K; Nitta K
    Nephrology (Carlton); 2009 Aug; 14(5):521-6. PubMed ID: 19674320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
    Ishii T; Kawamura T; Tsuboi N; Ogura M; Utsunomiya Y; Hosoya T
    Contrib Nephrol; 2007; 157():114-9. PubMed ID: 17495447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
    Komatsu H; Fujimoto S; Sato Y; Hara S; Yamada K; Morita S; Eto T
    J Nephrol; 2005; 18(6):690-5. PubMed ID: 16358226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation.
    Moriyama T; Nitta K; Suzuki K; Honda K; Horita S; Uchida K; Yumura W; Tanabe K; Toma H; Nihei H; Yamaguchi Y
    Clin Transplant; 2005; 19 Suppl 14():41-8. PubMed ID: 15955168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases.
    Kobayashi Y; Fujii K; Hiki Y; Tateno S
    Q J Med; 1986 Oct; 61(234):935-43. PubMed ID: 3628707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.